DPP4 and COVID-19: The clinical course of COVID-19 may also be modulated by the type of antidiabetic drug the patient is receiving, as SGLT2 inhibitors and GLP1R agonists could exacerbate the infection while DPP4 inhibitors may act as mitigators (Mirabelli et al., 2020).